Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Søk Study Connect

Recruiting

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors - CA233-0000

Oppdatert: 28 oktober, 2024   |   ClinicalTrials.gov

Utskriftsvennlig Sammendrag

VURDERER DU DENNE STUDIEN?
Skriv ut denne siden og studieveiledningen for å hjelpe deg å snakke med legen din.
Bruk Veiledning for studiedeltakere til å navigere gjennom deltakerprosessen i en klinisk studie. Forstå viktige faktorer å vurdere før du bestemmer deg og motta spørsmål som du kan stille til helsepersonalet ditt.

Vis detaljer

  • Phase 1

    Fase

  • Kjønn

  • 18+

    Aldersgruppe

  • 11

    Sted(er)

  • Recruiting

Behandlingsalternativer

Studiearmer
TILDELT INTERVENSJON
Experimental: Part 1A: BMS-986484 Dose Escalation
Drug: BMS-986484
Experimental: Part 1B: BMS-986484 + Nivolumab Dose Escalation
Drug: BMS-986484 Biological: Nivolumab
Experimental: Part 2A: BMS-986484 Dose Expansion
Drug: BMS-986484
Experimental: Part 2B: BMS-986484 + Nivolumab Dose Expansion
Drug: BMS-986484 Biological: Nivolumab

Nøkkelkriterier for kvalifikasjon

Inclusion Criteria: - Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN). - Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1). - Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1. Exclusion Criteria: - History of or with active interstitial lung disease or pulmonary fibrosis. - Active, known, or suspected autoimmune disease. - Serious uncontrolled medical disorders. - New onset, non-catheter-associated venous thromboembolism within the past 6 months. - Other protocol-defined Inclusion/Exclusion criteria apply.

Vi anbefaler at du kontakter BMS for å rapportere bivirkninger.
Bivirkninger (uønskede hendelser) og andre rapporterbare hendelser er definert her
For å rapportere bivirkninger (uønskede hendelser) eller reklamere på et legemiddel: Medisinsk informasjon

MLTNO2000046